Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized placebo-controlled proof-of-concept study of ATV-1601 in hereditary hemorrhagic telangiectasia
MOH_2026-10-13_017083Phase 2Not yet recruiting
- Sponsor
- Atavistik Bio
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ATV-1601 in hereditary hemorrhagic telangiectasia (HHT) (5 arms), sponsored by Atavistik Bio. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ATV-1601
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on MOH_2026-10-13_017083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-10-13_017083.